2 results
Approved WMOPending
Main objectiveStep 1: To determine the recommended phase 2 dose (RP2D) of MEN1611 when administered orally in combination with cetuximab to patients with PIK3CA mutated colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing…
Approved WMOSuspended
The aim of this study is to identify whether it is possible to safely discontinue treatment in stable RRMS patients who have shown no evidence of active inflammation in the years prior to inclusion in terms of the return of inflammatory disease…